Real-World check: Osimertinib's performance in spanish lung cancer patients under the microscope
NCT ID NCT06068049
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This study observes 500 Spanish patients with EGFR-mutated non-small cell lung cancer who are taking osimertinib in routine care. It aims to measure survival, quality of life, and how long patients stay on treatment. The goal is to see if results from clinical trials hold up in real life, especially for groups often left out of studies, like older patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- osimertinib
- What this could lead to
- If successful, this study could confirm that osimertinib works as well in real-world settings as in clinical trials, especially for older patients or those with rare mutations.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. It only looks at patients in Spain, so findings may not apply elsewhere.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
RECRUITINGA Coruña, Spain
-
Research Site
RECRUITINGAlicante, Spain
-
Research Site
RECRUITINGBarcelona, Spain
-
Research Site
RECRUITINGC Rdoba, Spain
-
Research Site
RECRUITINGEl Palmar, Spain
-
Research Site
RECRUITINGGirona, Spain
-
Research Site
RECRUITINGGranada, Spain
-
Research Site
RECRUITINGJaén, Spain
-
Research Site
RECRUITINGLas Palmas de Gran Canaria, Spain
-
Research Site
RECRUITINGLeón, Spain
-
Research Site
RECRUITINGLleida, Spain
-
Research Site
RECRUITINGMadrid, Spain
-
Research Site
WITHDRAWNMadrid, Spain
-
Research Site
RECRUITINGMálaga, Spain
-
Research Site
RECRUITINGOurense, Spain
-
Research Site
RECRUITINGPalma, Spain
-
Research Site
RECRUITINGSabadell, Spain
-
Research Site
RECRUITINGSalamanca, Spain
-
Research Site
RECRUITINGSanta Cruz de Tenerife, Spain
-
Research Site
ACTIVE_NOT_RECRUITINGSantander, Spain
-
Research Site
RECRUITINGSantiago de Compostela, Spain
-
Research Site
RECRUITINGSeville, Spain
-
Research Site
RECRUITINGValencia, Spain
-
Research Site
RECRUITINGValladolid, Spain
-
Research Site
RECRUITINGVigo, Spain
-
Research Site
RECRUITINGZaragoza, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?